NC
ABBV icon

nVerses Capital’s AbbVie ABBV Stock Holding History

nVerses Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$730K Buy
+2,900
New +$624K 1.12% 2
2024
Q4 		– Sell
-2,200
Closed -$434K – 4
2024
Q3 		$434K Buy
2,200
+500
+29% +$93.3K 0.2% 156
2024
Q2 		$292K Buy
+1,700
New +$282K 0.17% 190

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

nVerses Capital's ABBV Position: Q2 2026 in Review

nVerses Capital opened a new position in AbbVie (ABBV) in Q2 2026: 2,900 shares worth $730K. The stake represents 1.12% of the portfolio and ranks #2 among its holdings. This is a return to the name: nVerses Capital previously reported a position in ABBV as recently as Q3 2024.

nVerses Capital first reported a position in ABBV in Q2 2024 and has held it in 3 quarters since. 4,232 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • nVerses Capital held 2,900 shares of AbbVie worth $730K as of Q2 2026.
  • AbbVie was a new nVerses Capital position in Q2 2026.
  • AbbVie made up 1.12% of nVerses Capital's portfolio in Q2 2026, its #2 holding.
  • nVerses Capital first reported a position in AbbVie in Q2 2024 and has held it in 3 quarters since.
  • 4,232 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.